C型肝炎ウイルス：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 13
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 25
3.1.3 Prognosis 26
3.2 Symptoms 26
4 Epidemiology 27
4.1 Risk Factors and Comorbidities 27
4.1.1 The Risk of Contracting HCV Is Almost 50 Times Higher Among Injection Drug Users 28
4.1.2 There Is a 10.9-fold Increased Risk of Developing HCV Infection through a Blood Transfusion 29
4.1.3 No Current Preventative Therapy to Reduce Perinatal Transmission 29
4.1.4 Metabolic Syndrome Is a Common Comorbidity in HCV-infected Individuals 29
4.1.5 Chronic Alcoholism Greatly Magnifies the Risk of HCC 30
4.1.6 Hepatitis B Virus and HCV Share Similar Modes of Transmission, Resulting in Co-infections 31
4.1.7 HCV/HIV Co-infection Complicates Treatment Options and Accelerates Liver Damage 31
4.2 Global Trends 32
4.2.1 US 32
4.2.2 5EU 33
4.2.3 Japan 36
4.2.4 Brazil 37
4.2.5 China 37
4.3 Forecast Methodology 38
4.3.1 Sources Used 38
4.3.2 Forecast Assumptions and Methods 42
4.3.3 Forecast Assumptions and Methods (HCV Genotypes) 45
4.3.4 Sources Not Used 48
4.4 Epidemiology Forecast (2012-2022) 49
4.4.1 Total Prevalent Cases of HCV 49
4.4.2 Age-Specific Prevalent Cases of HCV 51
4.4.3 Sex-Specific Prevalent Cases of HCV 54
4.4.4 Age-Standardized Prevalence of HCV 55
4.4.5 HCV Genotype Class Distributions 57
4.5 Discussion 58
4.5.1 Conclusion on Epidemiology Trends 58
4.5.2 Limitations of the Analysis 59
4.5.3 Strengths of the Analysis 59
5 Disease Management 60
5.1 Diagnosis and Referral Overview 60
5.2 Treatment Overview 61
5.3 US 64
5.3.1 Diagnosis 64
5.3.2 Clinical Practice 66
5.4 France 68
5.4.1 Diagnosis 68
5.4.2 Clinical Practice 69
5.5 Germany 70
5.5.1 Diagnosis 70
5.5.2 Clinical Practice 70
5.6 Italy 71
5.6.1 Diagnosis 71
5.6.2 Clinical Practice 72
5.7 Spain 72
5.7.1 Diagnosis 72
5.7.2 Clinical Practice 73
5.8 UK 74
5.8.1 Diagnosis 74
5.8.2 Clinical Practice 75
5.9 Japan 75
5.9.1 Diagnosis 75
5.9.2 Clinical Practice 76
5.10 Brazil 77
5.10.1 Diagnosis 77
5.10.2 Clinical Practice 77
5.11 China 78
5.11.1 Diagnosis 78
5.11.2 Clinical Practice 78
6 Competitive Assessment 79
6.1 Overview 79
6.2 Strategic Competitor Assessment 79
6.3 Product Profiles – Major Brands 81
6.3.1 Incivek (telaprevir) 81
6.3.2 Victrelis (boceprevir) 87
6.3.3 Pegasys (peginterferon alfa-2a) 93
6.3.4 PegIntron (peginterferon alfa-2b) 98
6.3.5 Copegus, Rebetol, and Generic Ribavirin 103
6.3.6 Therapeutic Class: Interferon 107
7 Opportunity and Unmet Need 108
7.1 Overview 108
7.2 Unmet Needs 109
7.2.1 Unmet Need: Treatment Tolerability 109
7.2.2 Unmet Need: Efficacy 109
7.2.3 Unmet Need: Disease Awareness 110
7.2.4 Unmet Need: Treatment Cost 111
7.2.5 Unmet Need: Shorter Treatment Duration 111
7.2.6 Unmet Need: Simplified Treatment Regimens 112
7.3 Unmet Needs Gap Analysis 112
7.4 Opportunities 113
7.4.1 Opportunity: Pan-genotypic HCV Regimen 113
7.4.2 Opportunity: Treatment of Underrepresented Patient Populations 113
7.4.3 Opportunity: Involvement of Immune System 114
8 Pipeline Assessment 115
8.1 Overview 115
8.2 Clinical Trial Mapping 116
8.2.1 Clinical Trials by Country 116
8.3 Clinical Trials by Phase and Trial Status 117
8.4 Promising Drugs in Clinical Development 118
8.4.1 Sofosbuvir and Sofosbuvir/Ledipasvir 119
8.4.2 Simeprevir 132
8.4.3 ABT-450 plus ABT-267 and ABT-333 140
8.4.4 Faldaprevir and Faldaprevir plus BI 207127 148
8.4.5 Daclatasvir and Daclatasvir plus Asunaprevir 157
8.4.6 Vaniprevir 166
8.4.7 Other Drug Classes 172
9 Current and Future Players 175
9.1 Overview 175
9.2 Trends in Corporate Strategy 177
9.3 Company Profiles 178
9.3.1 Merck 178
9.3.2 Roche 180
9.3.3 Vertex 182
9.3.4 Janssen 183
9.3.5 Gilead 185
9.3.6 AbbVie 188
9.3.7 Bristol-Myers Squibb 190
9.3.8 Boehringer Ingelheim 192
9.4 Additional Companies with Promising Drugs 193
9.4.1 Mitsubishi Tanabe 193
9.4.2 GlaxoSmithKline 194
9.4.3 Achillion 195
9.4.4 Scynexis 196
9.4.5 Idenix 196
9.4.6 Presidio 197
10 Market Outlook 199
10.1 Global Markets 199
10.1.1 Forecast 199
10.1.2 Drivers and Barriers – Global Issues 203
10.2 US 207
10.2.1 Forecast 207
10.2.2 Key Events 212
10.2.3 Drivers and Barriers 212
10.3 France 216
10.3.1 Forecast 216
10.3.2 Key Events 221
10.3.3 Drivers and Barriers 221
10.4 Germany 223
10.4.1 Forecast 223
10.4.2 Key Events 228
10.4.3 Drivers and Barriers 228
10.5 Italy 230
10.5.1 Forecast 230
10.5.2 Key Events 234
10.5.3 Drivers and Barriers 234
10.6 Spain 236
10.6.1 Forecast 236
10.6.2 Key Events 240
10.6.3 Drivers and Barriers 240
10.7 UK 242
10.7.1 Forecast 242
10.7.2 Key Events 247
10.7.3 Drivers and Barriers 247
10.8 Japan 249
10.8.1 Forecast 249
10.8.2 Key Events 254
10.8.3 Drivers and Barriers 254
10.9 Brazil 256
10.9.1 Forecast 256
10.9.2 Key Events 260
10.9.3 Drivers and Barriers 260
10.10 China 262
10.10.1 Forecast 262
10.10.2 Key Events 266
10.10.3 Drivers and Barriers 266
11 Appendix 268
11.1 Bibliography 268
11.2 Abbreviations 291
11.3 Methodology 293
11.4 Forecasting Methodology 293
11.4.1 Percent Drug-Treated Patients 293
11.4.2 Patient Warehousing 294
11.4.3 Drugs Included in Each Therapeutic Class 294
11.4.4 Launch and Patent Expiry Dates 295
11.4.5 General Pricing Assumptions 296
11.4.6 Individual Drug Assumptions 296
11.4.7 Generic Erosion 299
11.4.8 Selection of Pipeline Agents 299
11.4.9 Pricing of Pipeline Agents 300
11.5 Physicians and Specialists Included in this Study 303
11.6 Survey of Prescribing Physicians 305
11.7 About the Authors 306
11.7.1 Author 306
11.7.2 Epidemiologist 306
11.7.3 Global Head of Healthcare 307
11.8 About GlobalData 308
11.9 Contact Us 308
11.10 Disclaimer 308